Development of effector cell-targeted treatment for the inhibition of type 1 diabetes

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591334
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Metabolomics
• Research Institution: Nagasaki University
• Principal Investigator: ABIRU Noriio 長崎大学, 医歯薬学総合研究科(医学系), 准教授 (00380981)
• Co-Investigator(Kenkyū-buntansha): AKAZAWA Satoru 長崎大学, 病院(医学系), 助教 (50549409)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 1型糖尿病 / NODマウス / Ｔ細胞 / サイトカイン / IRF4 / グランザイムＢ

Outline of Final Research Achievements

In order to identify the candidate molecules for the development of the effector cell-targeted treatment for the inhibition of type 1 diabetes, we have developed IL-17/IFN-gamma receptor-double-deficient, Granzyme B-deficient, IRF4-deficient NOD mice. IL-17/IFN-gamma R double-deficiency significantly suppressed the development of diabetes, while independent deletion of IL-17 or IFN-gammaR did not alter the disease susceptibility in NOD mice. Granzyme B-deficient NOD mice spontaneously developed diabetes with similar kinetics to wild-type NOD mice. Diabetes/insulitis and autoantibody production were completely suppressed in IRF4-deficient heterozygous as well as homozygous NOD mice. These suggest that the an IRF4-targeted strategy may be useful for modulating autoimmunity in type 1 diabetes.

Free Research Field

代謝学